Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Colorectal Cancer Stage IV Clinical Trial

Official title:

A Randomized, Open, Multicenter Phase III Clinical Trial of Combination of Sintilimab Injection (IBI308) and XELOX+Bevacizumab Compared With XELOX+Bevacizumab as 1st Line Therapy of RAS-Mutant Metastatic Colorectal Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05171660
• Other study ID #: 2021-1013
• Status: Recruiting
• Phase: Phase 3
• Start date: February 8, 2022
• Est. completion date: June 30, 2025

Study information

• Verified date: October 2022
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: XUEFENG FANG
• Phone: 057187784718
• Email: xffang[@]zju.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Sintilimab (R&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody. PD-1 inhibitor combined with chemotherapy has synergistic effect to further enhance anti-tumor immunity. This study is a phase III clinical study of a three-week regimen of sintilimab combined with the XELOX+ bevacizumab for RAS-mutant metastatic colorectal cancer patients who had not received any treatment before. The purpose of this study is to explore the efficacy of sintilimab combined with XELOX + bevacizumab as first line therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 436
• Est. completion date: June 30, 2025
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or female, age = 18 years old, = 75 years old

2. Metastatic colorectal adenocarcinoma confirmed by histology, metastases cannot be removed

3. RAS mutation

4. ECOG 0 to 1

5. Life expectancy is at least 12 weeks

6. Hematological examination absolute neutrophil count (ANC)>1.5×109/L, hemoglobin>8g/dL and platelet>100×109/L (according to the normal value of clinical trial center)

7. Prothrombin time (PT) < 1.5 times the upper limit of normal value and normal thromboplastin time (APTT) < 1.5 times the upper limit of normal value

8. Laboratory examination, serum creatinine is less than or equal to 1.5 times the upper limit of the normal reference range (if serum creatinine is elevated, 24 hours of urine must be collected, except for 24 hours creatinine clearance > 50ml/min)

9. When there is no liver metastasis, ALT or AST is less than or equal to 2.5 times the upper limit of the normal value reference range, serum total bilirubin is less than or equal to 1.5 times the upper limit of the normal value reference range; for patients with liver metastasis, ALT or AST is less than or equal to 5 times the upper limit of the normal value reference range, serum total bilirubin is less than or equal to 3 times the upper limit of the normal value reference range

10. Women of childbearing age must be willing to use adequate contraception during study drug treatment

11. Informed consent has been signed

12. According to the definition of RECIST 1.1, the investigator determined that the patient had a measurable disease. Tumor lesions located in previous radiotherapy areas are considered measurable if they demonstrate progression.

Exclusion Criteria:

1. Active autoimmune disease requiring systemic treatment occurred in the previous 2 years.

2. Diagnosed as immunodeficiency or experimental treatment is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose. After consultation with the sponsor, the use of a physiological dose of corticosteroids may be approved.

3. Adverse events caused by anti-tumor monoclonal antibodies (mAbs) within 4 weeks prior to study day 1 or drugs received 4 weeks prior to the study have not recovered.

4. Adverse events caused by chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1, or previously received drugs, have not recovered (ie, =1 or reached baseline levels).

Other malignancies that are progressing or require active treatment are known. Except for basal cell carcinoma, cutaneous squamous cell carcinoma, or cervical carcinoma in situ that have undergone radical treatment.

5. Active central nervous system (CNS) metastasis and/or cancerous meningitis are known to exist.

6. There are active infections that require systemic treatment.

7. It is possible to confuse the test results, the medical history or disease evidence, the treatment or laboratory value abnormalities that hinder the subject's full participation in the study, or the investigator believes that participating in the study is not in the best interests of the subject.

8. There are known mental or substance abuse disorders that may have an impact on compliance with test requirements.

9. Female subjects who are pregnant or lactating, or who are expected to be pregnant during the planned trial period (from 120 days after screening visits to 120 days after the last dose of study treatment, or 180 days after the last dose of study treatment), or Male subjects whose spouse is pregnant.

10. A history of infection with human immunodeficiency virus (HIV) (HIV 1/2 antibody) is known.

11. Active hepatitis B or C.

12. Live vaccines were vaccinated within 30 days of the start date of the study treatment plan.

13. RAS wild type

Related Conditions & MeSH terms

• Colorectal Cancer Stage IV
• Colorectal Neoplasms

Intervention

Drug:
• Sintilimab Injection
Sintilimab Injection: 200 mg, i.v., D1, Q3W, 8 courses
• Control Test
XELOX + Bevacizumab

Locations

Country	Name	City	State
China	Xuefeng Fang	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival time	Progression-free survival is defined as the time from enrollment to the first documented disease progression according to RECIST version 1.1, or to death from any cause, whichever occurred first.	From Baseline to primary completion date, about 2 years
Secondary	Overall survival time		12 months
Secondary	Objective Response Rate		12 months
Secondary	Adverse Events		12 months